Sopharma AD-SofiaWAR:SPH +8.49%67 Piotroski F-Score is 6 as of Jun. 26, 2026, which is 50% above its 10-year median of 4.00. GuruFocus rates WAR:SPH with a GF Score™ of 67/100 and a GF Value™ of zł13.56 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 114 Medical Distribution companies, Sopharma AD-Sofia ranks better than 76.32% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Sopharma AD-Sofia has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.
The historical rank and industry rank for Sopharma AD-Sofia's Piotroski F-Score or its related term are showing as below:
WAR:SPH'
s Piotroski F-Score Range Over the Past 10 Years
Min: 1 Med: 4 Max: 7
Current: 6
During the past 13 years, the highest Piotroski F-Score of Sopharma AD-Sofia was 7. The lowest was 1. And the median was 4.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Sopharma AD-Sofia Piotroski F-Score Related Terms
Sopharma AD-Sofia Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Sopharma AD-Sofia's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:SPH vs MCK, COR, CAH: Piotroski F-Score Comparison
For the Medical Distribution subindustry, Sopharma AD-Sofia's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sopharma AD-Sofia Piotroski F-Score vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Sopharma AD-Sofia's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Mar26) TTM:
Last Year (Mar25) TTM:
Net Income was 64.338 + 88.872 + 40.352 + 134.674 = zł328 Mil. Cash Flow from Operations was -36.801 + 25.218 + 121.28 + 74.27 = zł184 Mil. Revenue was 1353.714 + 1399.107 + 1540.255 + 1499.024 = zł5,792 Mil. Gross Profit was 299.301 + 330.487 + 377.087 + 378.855 = zł1,386 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(3949.708 + 4256.723 + 4431.238 + 4553.599 + 4553.874) / 5 = zł4349.0284 Mil. Total Assets at the begining of this year (Mar25) was zł3,950 Mil. Long-Term Debt & Capital Lease Obligation was zł463 Mil. Total Current Assets was zł2,398 Mil. Total Current Liabilities was zł1,740 Mil.
Net Income was 32.458 + 38.708 + 23.217 + 81.91 = zł176 Mil.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Sopharma AD-Sofia's current Net Income (TTM) was 328.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Sopharma AD-Sofia's return on assets of this year was 0.08310386. Sopharma AD-Sofia's return on assets of last year was 0.05341273.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Sopharma AD-Sofia's gearing of this year was 0.10644837. Sopharma AD-Sofia's gearing of last year was 0.13892392.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Sopharma AD-Sofia's current ratio of this year was 1.37772222. Sopharma AD-Sofia's current ratio of last year was 1.23721105.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Sopharma AD-Sofia's number of shares in issue this year was 551.364. Sopharma AD-Sofia's number of shares in issue last year was 166.362.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Sopharma AD-Sofia's gross margin of this year was 0.23924483. Sopharma AD-Sofia's gross margin of last year was 0.21659718.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Sopharma AD-Sofia's asset turnover of this year was 1.46646284. Sopharma AD-Sofia's asset turnover of last year was 1.38308449.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
1
+
0
+
1
+
1
+
0
+
1
+
1
=
7
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Sopharma AD-Sofia has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.
Sopharma AD-Sofia (WAR:SPH) has a Piotroski F-Score of 6 as of Jun. 26, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Sopharma AD-Sofia and its competitors. This is 50% above median its historical median of 4.00. Over the past decade, Sopharma AD-Sofia's Piotroski F-Score has ranged from 1.00 to 7.00. According to the industry distribution chart, Sopharma AD-Sofia ranks #27 out of 114 companies in the Medical Distribution industry, placing it in the top 23.7%.
Is Sopharma AD-Sofia's Piotroski F-Score too high?
Sopharma AD-Sofia's current Piotroski F-Score of 6 is 50% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 7.00. The Medical Distribution industry median Piotroski F-Score is 5.00. Sopharma AD-Sofia's value of 6 is 20% above this industry median. Based on the distribution chart, Sopharma AD-Sofia ranks #27 out of 114 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Sopharma AD-Sofia has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's Piotroski F-Score compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sopharma AD-Sofia ranks #27 out of 114 companies for Piotroski F-Score. This places Sopharma AD-Sofia in the top 24% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Sopharma AD-Sofia's value of 6 is 20% above this benchmark. Historically, Sopharma AD-Sofia's own Piotroski F-Score has ranged from 1.00 to 7.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, Sopharma AD-Sofia has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Distribution company?
The median Piotroski F-Score among Medical Distribution companies is 5.00, based on 114 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sopharma AD-Sofia's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Sopharma AD-Sofia and its competitors. For the Medical Distribution industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sopharma AD-Sofia's current Piotroski F-Score is 6, which is 50% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (WAR:SPH) is currently considered Possible Value Trap. The stock's GF Value™ is zł13.56, compared to a current price of zł7.92 — trading 41.6% below its estimated fair value. The current Piotroski F-Score is 6, which is 50% above median its 10-year median of 4.00 and 20% above the Medical Distribution industry median of 5.00. Sopharma AD-Sofia's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Sopharma AD-Sofia (WAR:SPH), the current Piotroski F-Score is 6 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma AD-Sofia (WAR:SPH) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be undervalued.
The current stock price of zł7.92 is trading 41.6% below its estimated GF Value™ of zł13.56.
GuruFocus considers Sopharma AD-Sofia to be Possible Value Trap.
Key valuation signals for WAR:SPH:
Piotroski F-Score: 6 (50% above median its 10-year median of 4.00)
GF Value™: zł13.56 vs. price of zł7.92 (41.6% below fair value)
Industry Position: 20% above the Medical Distribution median (#27 of 114)
No single metric tells the full story. See the WAR:SPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
67GF Score
Get the complete analysis for WAR:SPH
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SPH has been successfully added to your 
